Differential expression of follistatin and FLRG in human breast proliferative disorders

BMC Cancer

Volumn 9, Issue , 2009, Pages 320-

  Bloise, Enrrico ^a,b   Couto, Henrique L ^a   Massai, Lauretta ^b   Ciarmela, Pasquapina ^c   Mencarelli, Marzia ^b   Borges, Lavinia E ^b   Muscettola, Michela ^b   Grasso, Giovanni ^b   Amaral, Vania F ^a   Cassali, Geovanni D ^a   Petraglia, Felice ^b   Reis, Fernando M ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; FOLLISTATIN; FOLLISTATIN RELATED PROTEIN; MESSENGER RNA;

ADULT; AGED; ARTICLE; BREAST FIBROADENOMA; BREAST HYPERPLASIA; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTRADUCTAL CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; UPREGULATION;

ADULT; AGED; BREAST NEOPLASMS; CELL NUCLEUS; CYTOPLASM; FEMALE; FOLLISTATIN; FOLLISTATIN-RELATED PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; PROTEIN TRANSPORT;

EID: 70349873221     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-320     Document Type: Article

References (37)

1. Risbridger GP, Schmitt JF, Robertson DM. Activins and inhibins in endocrine and other tumors. Endocr Rev 2001, 22:836-858. 10.1210/er.22.6.836, 11739336.
2. Di Loreto C, Reis FM, Cataldi P, Zuiani C, Luisi S, Beltrami CA, Petraglia F. Human mammary gland and breast carcinoma contain immunoreactive inhibin/activin subunits: evidence for a secretion into cystic fluid. Eur J Endocrinol 1999, 141:190-194. 10.1530/eje.0.1410190, 10427163.
3. Reis FM, Cobellis L, Tameirao LC, Anania G, Luisi S, Silva IS, Gioffre W, Di Blasio AM, Petraglia F. Serum and tissue expression of activin A in postmenopausal women with breast cancer. J Clin Endocrino Metab 2002, 87:2277-2282.
4. Jeruss JS, Sturgis CD, Rademaker AW, Woodruff TK. Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer. Cancer Res 2003, 63:3783-3790.
5. Liu QY, Niranjan B, Gomes P, Gomm JJ, Davies D, Coombes RC, Buluwela L. Inhibitory effects of activin on the growth and morpholgenesis of primary and transformed mammary epithelial cells. Cancer Res 1996, 56:1155-1163.
6. Burdette JE, Jeruss JS, Kurley SJ, Lee EI, Woodruff TK. Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells. Cancer Res 2005, 65:7968-7975.
7. Burdette JE, Woodruff TK. Activin and estrogen crosstalk regulates trancriptional and cell cycle control in human breast cancer cells. Endocr Relat Cancer 2007, 14:679-689. 10.1677/ERC-07-0054, 17914098.
8. Lin SJ, Lerch TF, Cook RW, Jardetzky TS, Woodruff TK. The structural basis of TGF-beta, bone morphogenetic protein, and activin ligand binding. Reproduction 2006, 132:179-190. 10.1530/rep.1.01072, 16885528.
9. Komatsu Y, Scott G, Nagy A, Kaartinen V, Mishina Y. BMP type I receptor ALK2 is essential for proper patterning at late gastrulation during mouse embryogenesis. Dev Dyn 2007, 236:512-517. 10.1002/dvdy.21021, 1780255, 17117439.
10. Harrison CA, Gray PC, Vale WW, Robertson MD. Antagonists of activin signaling: mechanisms and potential biological applications. Trends Endocrinol Metab 2005, 16:73-78. 10.1016/j.tem.2005.01.003, 15734148.
11. Hashimoto O, Tsuchida K, Ushiro Y, Hosoi Y, Hoshi N, Sugino H, Hasegawa Y. cDNA cloning and expression of human activin betaE subunit. Mol Cell Endocrinol 2002, 194:117-122. 10.1016/S0303-7207(02)00157-0, 12242034.
12. Schneyer A, Schoen A, Quigg A, Sidis Y. Differential binding and neutralization of activins A and B by follistatin and follistatin like-3 (FSTL-3/FSRP/FLRG). Endocrinology 2003, 144:1671-1674. 10.1210/en.2002-0203, 12697670.
13. Glister C, Kemp CF, Knight PG. Bone morphogenetic protein (BMP) ligands and receptors in bovine ovarian follicle cells: actions of BMP-4, -6 and -7 on granulosa cells and differential modulation of Smad-1 phosphorylation by follistatin. Reproduction 2004, 127:239-254. 10.1530/rep.1.00090, 15056790.
14. Lee SJ, Mcpherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci 2001, 98:9306-9311. 10.1073/pnas.151270098, 55416, 11459935.
15. Hill JJ, Davies MV, Pearson AA, Wang JH, Hewick RM, Wolfman NM, Qiu Y. The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem 2002, 277:40735-40741. 10.1074/jbc.M206379200, 12194980.
16. Chen YG, Wang Q, Lin SL, Chang CD, Chuang J, Ying SY. Activin signaling and its role in regulation of cell proliferation, apoptosis, and carcinogenesis. Exp Biol Med 2006, 231:534-544.
17. Razanajaona D, Joguet S, Ay AS, Treilleux I, Goddard-Leon S, Bartholin L, Rimokh R. Silencing of FLRG, an antagonist of activin, inhibits human breast tumor cell growth. Cancer Res 2007, 67:7223-7229. 10.1158/0008-5472.CAN-07-0805, 17671190.
18. Deli A, Kreidl E, Santifaller S, Trotter B, Seir K, Berger W, Schulte-Hermann R, Rodgarkia-Dara C, Grusch M. Activins and activin antagonists in hepatocellular carcinoma. World J Gastroenterol 2008, 21:1699-1709.
19. Ogino H, Yano S, Kakiuchi S, Muguruma H, Ikuta K, Hanibuchi M, Uehara H, Tsuchida K, Sugino H, Sone S. Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice. Clin Cancer Res 2008, 14:660-667. 10.1158/1078-0432.CCR-07-1221, 18245525.
20. Krneta J, Kroll J, Alves F, Prahst C, Sananbenesi F, Dullin C, Kimmina S, Phillips DJ, Augustin HG. Dissociation of angiogenesis and tumorigenesis in follistatin- and activin-expressing tumors. Cancer Res 2006, 66:5686-5695. 10.1158/0008-5472.CAN-05-3821, 16740706.
21. Ciarmela P, Florio P, Sigurdardottir M, Toti P, Maguer-Satta V, Rimokh R, Altomare A, Tosi P, Petraglia F. Follistatin-related gene expression, but not follistatin expression, is decreased in human endometrial adenocarcinoma. Eur J Endocrinol 2004, 151:251-257. 10.1530/eje.0.1510251, 15296481.
22. Torres PB, Florio P, Ferreira MC, Torricelli M, Reis FM, Petraglia F. Deranged expression of follistatin and follistatin-like protein in women with ovarian endometriosis. Fertil Steril 2007, 88:200-205. 10.1016/j.fertnstert.2006.11.105, 17296189.
23. Ferreira MC, Cavallo IK, Florio P, Petraglia F, Reis FM. Activin betaA subunit, follistatin and follistatin-like 3 are expressed in the endometrium of ovariectomized rats and regulated by estrogen replacement. J Mol Histol 2008, 39:535-541. 10.1007/s10735-008-9194-x, 18781389.
24. Maguer-Satta V, Bartholin L, Jeanpierre S, Gadoux M, Bertrand S, Martel S, Magaud JP, Rimokh R. Expression of FLRG, a novel activin A ligand, is regulated by TGF-beta and during hematopoiesis. Exp Hematol 2001, 29:301-308. 10.1016/S0301-472X(00)00675-5, 11274757.
25. Florio P, Ciarmela P, Toti P, Maguer-Satta V, Rimokh R, Buonocore G, Rossi M, Gioffrè W, Petraglia F. Human endometrium and decidua express follistatin-related gene (FLRG) mRNA and peptide. Mol Cell Endocrinol 2004, 218:129-135. 10.1016/j.mce.2003.12.019, 15130517.
26. Klein SC, van Wichen DF, Golverdingen JG, Jacobse KC, Broekhuizen R, de Weger RA. An improved, sensitive, non-radioactive in situ hybridization method for the detection of cytokine mRNAs. APMIS 1995, 103:345-353. 10.1111/j.1699-0463.1995.tb01118.x, 7654359.
27. Massai L, Carbotti P, Cambiaggi C, Mencarelli M, Migliaccio P, Muscettola M, Grasso G. Prepro-endothelin-1 mRNA and its mature peptide in human appendix. Am J Physiol Gastrointest Liver Physiol 2003, 284:340-348.
28. Reis FM, Luisi S, Carneiro MM, Cobellis L, Federico M, Camargos AF, Petraglia F. Activin, inhibin and the human breast. Mol Cell Endocrinol 2004, 225:77-82. 10.1016/j.mce.2004.02.016, 15451571.
29. Courtillot C, Plu-Bureau G, Binart N, Balleyguier C, Sigal-Zafrani B, Goffin V, Kuttenn F, Kelly PA, Touraine P. Benign breast diseases. J Mammary Gland Biol Neoplasia 2005, 10:325-335. 10.1007/s10911-006-9006-4, 16900392.
30. Bussmann UA, Lanuza GM, Bussmann LE. Activin and follistatin in rat mammary gland. Mol Cell Endocrinol 2004, 30:9-19.
31. Page DL, Dupont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 1982, 49:751-758. 10.1002/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y, 6275978.
32. Saito S, Sidis Y, Mukherjee A, Xia Y, Schneyer A. Differential biosynthesis and intracellular transport of follistatin isoforms and follistatin-like-3. Endocrinology 2005, 146:5052-5062. 10.1210/en.2005-0833, 16150905.
33. Refaat B, Amer S, Ola B, Chapman N, Ledger W. The expression of activin-betaA- and -betaB-subunits, follistatin, and activin type II receptors in fallopian tubes bearing an ectopic pregnancy. J Clin Endocrinol Metab 2008, 93:293-299. 10.1210/jc.2007-1654, 17971430.
34. Ogawa K, Hashimoto O, Kurohmaru M, Mizutani T, Sugino H, Hayashi Y. Follistatin-like immunoreactivity in the cytoplasm and nucleus of spermatogenic cells in the rat. Eur J Endocrinol 1997, 137:523-529. 10.1530/eje.0.1370523, 9405033.
35. Welt C, Sidis Y, Keutmann H, Schneyer A. Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Exp Biol Med 2002, 227:724-752.
36. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-49. 10.1016/S1535-6108(03)00132-6, 12842083.
37. Massagué J. TGFbeta in Cancer. Cell 2008, 134:215-30. 10.1016/j.cell.2008.07.001, 18662538.